Lenacapavir shot offers hope, but access is constrained
Lindiwe Mqatazana is not taking any chances with her health, or with that of her unborn child. “There…
Compugen Highlights AI-Driven IO Pipeline, Key Trial Timelines and Big Pharma Partnerships at Needham Conference
Compugen logo Compugen leverages its AI-driven discovery engine, Unigen, to identify novel immuno-oncology targets and advance select assets…
HIV can develop resistance to lenacapavir, but at a cost to the virus
Since its first approval in 2022, Gilead Sciences’ lenacapavir—a twice-yearly injectable—has come to be a potential game…
How the Gym Helped Me Discover My True Self
For U.S. audiences only SELF-ACCEPTANCE IS A complicated, ongoing journey that can be as demanding as it is…
Twice-a-year injection could make HIV prevention easier, developer argues
A twice-a-year shot for HIV prevention could make it easier for people to protect themselves from the virus,…